News

Immunic to Showcase Innovative Therapies at Key Conferences

Immunic to Showcase Innovative Therapies at Key Conferences

Immunic Announces Participation in February Conferences

Immunic, Inc. (Nasdaq: IMUX), a pioneering biotechnology firm, is gearing up to present its latest advancements in drug development at several key investor and scientific conferences throughout February. These events will provide an excellent platform for sharing insights on their innovative therapies aimed at addressing chronic inflammatory and autoimmune diseases.

Upcoming Events Featuring Immunic

The conferences where Immunic will be participating include:

  • February 10-11: The BIO CEO & Investor Conference 2025, where Daniel Vitt, Ph.D., CEO of Immunic, will engage in one-on-one meetings. This event promises valuable discussions on the evolving landscape of biotechnology and therapeutics.
  • February 11-12: The Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr. Vitt will also participate in a fireside chat, offering insights into Immunic's vision and progress in clinical development.
  • February 19-22: The 19th Congress of the European Crohn's and Colitis Organisation (ECCO) in Berlin. Immunic's scientific team will present two impactful abstracts related to their flagship drug, IMU-856, focused on regenerative therapies.
  • February 25-27: The 7th Neuroimmunology Drug Development Summit in Boston, where Hella Kohlhof, Ph.D., will showcase their leading therapy, vidofludimus calcium (IMU-838), exploring its combined neuroprotective and anti-inflammatory capabilities.
  • February 27 - March 1: The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. Immunic's team will provide insights from two accepted poster presentations, further advancing discussions on multiple sclerosis treatments.

Highlighting Immunic's Groundbreaking Research

At these conferences, Immunic will highlight its lead programs, notably vidofludimus calcium (IMU-838), which is in pivotal trials targeting relapsing and progressive forms of multiple sclerosis. This therapy harnesses a dual mechanism, acting as a nuclear receptor related 1 (Nurr1) activator while inhibiting dihydroorotate dehydrogenase (DHODH) to produce both neuroprotective and anti-inflammatory effects.

Additionally, the conference presentations will cover IMU-856, a novel orally administered modulator designed to enhance intestinal barrier integrity and support bowel health. Its investigational applications also extend to autoimmune disorders, showcasing its potential in treating various gastrointestinal conditions.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) continues to innovate in the field of biotechnology, developing a rich pipeline of orally available therapies tailored for chronic inflammatory and autoimmune diseases. Their commitment to research excellence positions them uniquely in the industry, promising advancements that can significantly improve patient outcomes. With lead candidates in late-stage clinical trials, Immunic's efforts are aligned with unmet medical needs.

For further context on their developments, the public can explore updates on Immunic's website, which offers an extensive overview of their ongoing clinical trials, therapeutic pipelines, and conference participation details.

Frequently Asked Questions

What is the focus of Immunic, Inc.'s research?

Immunic focuses on developing orally available therapies specifically for chronic inflammatory and autoimmune diseases.

Which major conferences will Immunic be attending?

Immunic will attend several conferences, including the BIO CEO & Investor Conference and the ECCO Congress.

What are the main drugs featured by Immunic at the conferences?

Immunic will primarily feature its lead drug, vidofludimus calcium (IMU-838), and another candidate, IMU-856.

What potential conditions do these drugs target?

These drugs target conditions like multiple sclerosis and other chronic inflammatory disorders.

How can I learn more about Immunic's products and research?

More information can be found on Immunic’s official website, detailing their pipeline and clinical developments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SK Bio Pushes FDA Approval for Cenobamate in Seizures

Updated Category News Views 66

Taking New Strides in Epilepsy Treatment Today, we’ve got SK Biopharmaceuticals banging on the FDA’s door with a pile of paperwork. They’re pushing for the green light on cenobamate to tackle primary generalized tonic-clonic (PGTC) seizures, plus expand its use to pediatric patients with the focal-onset seizure condition. Now, if you think it sounds like a big...

Continue Reading
Fast Renovations Could Save Homeowners Big Bucks

Updated Category News Views 116

Speed Matters in Renovation Projects You ever been locked in that eternal waiting game with a renovation project? It's a killer for the wallet. Chapter Renovation's digging into this mess, showing how dragging out a project can cost homeowners plenty more than they bargained for. They've been pushing an average completion time of 38 weeks. Compare that to the chilling...

Continue Reading
Life with PAH: A Journey of Awareness and Hope

Updated Category News Views 230

Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...

Continue Reading
Ampace Shifts Focus to Reliability in Two-Wheeler Batteries

Updated Category News Views 88

Here's a Shift: Reliability Over Specs Alright, folks, buckle up because Ampace is shaking things up at EICMA Milan this year. While some are still yammering on about juicing up specs, Ampace is talking reliability. It's a bold move in the fast-evolving two-wheeler battery market, where everyone's been obsessed with horsepower and max speeds. The landscape's shifting...

Continue Reading
American Prosperity Rises Despite Economic Concerns

Updated Category News Views 82

Reading Between the Lines of Prosperity You'd think the headlines scream gloom—job insecurity, a shaky economy, ridiculous basic cost hikes. Yet, against the odds like an underdog scrapping past the finish line, the Northwestern Mutual's Personal Prosperity Index crawled up to 71 out of 100, up by a humble three points since mid-year. Unlocking Prosperity in Chaotic...

Continue Reading
Lululemon Faces Lawsuit Over Alleged Fraudulent Reporting

Updated Category News Views 173

What's Stirring the Pot for Lululemon? Talk about a rollercoaster. Over here, Lululemon (NASDAQ:LULU) is navigating turbulent waters, facing a class action lawsuit for alleged securities fraud. Investors who bought into the brand between March 18, 2026, and September 3, 2026, are now watching their investments drop, following what's claimed as misleading trumpet calls...

Continue Reading
Ecobat Workers Secure Landmark Three-Year Contract

Updated Category News Views 60

A Breakthrough for Ecobat Workers Man, when it comes to contracts, this recent deal at Ecobat is as game-changing as they get. A vote just ripped through like a hurricane, with 220 workers under Teamsters Local 986 eagerly ratifying a new three-year agreement that signals more than just a better payday. We're talking the largest wage boost these folks have clapped eyes on...

Continue Reading
Midterm Election Insights: Border Enforcement Debate Heats Up

Updated Category News Views 101

The Midterm Aftermath: What Really Matters So the ballots are counted, and once again, the shiny chatter about midterms seemed to orbit more around wallet aches and foreign skirmishes than dusty border control debates. But, dig a bit deeper—like poking at a sore spot—and you'll find border security sitting patiently in the wings. Not gone, just waiting for its...

Continue Reading
Ceva's Bluetooth HDT Boosts Wireless Connectivity

Updated Category News Views 59

Bluetooth HDT: The Next Leap in Connectivity Ceva's been in the game long before the rules were even set. With the introduction of Bluetooth High Data Throughput (HDT), they're not just playing; they're innovating. This tech doesn't just boost connectivity—it multiplies it, enhancing Bluetooth's reliability and energy efficiency while quadrupling data throughput. That's...

Continue Reading
Agthia Navigates Tough Terrain, Reports Impressive Growth

Updated Category News Views 84

Agthia's Q3 2026: A Balancing Act Between Growth and Costs When the going gets tough, the tough navigate strategic pivots. Agthia Group PJSC (AGTHIA:UH) isn't just sitting back and watching; they're charging ahead. They've rolled out their Q3 figures and, boy, it's a mix of hurdles and high jumps. With a 14.4% spike in revenue to AED 1.3 billion, it's clear they're not...

Continue Reading

Top 5 Most Recently Viewed Articles

Planet Labs Boosted by Impressive Q2 Earnings Performance

Updated Category News Views 127

Market Overview and Stock Movements The U.S. stock market experienced a mixed day as traders gauged the recent economic indicators and their implications on financial performance. The Nasdaq Composite stood out with a notable gain of approximately 150 points, reflecting a 0.70% increase to reach 21,851.83. Meanwhile, the Dow Jones Industrial Average faced a slight...

Continue Reading
AS Tallink Grupp Reports Significant Passenger Changes

Updated Category News Views 181

AS Tallink Grupp's March and First Quarter Performance Overview In a recent report, AS Tallink Grupp announced their transportation statistics for March and the first quarter of the year. The company, known for its passenger and cargo transportation services, has experienced significant changes in its performance metrics. Passenger Transportation Insights For the month of...

Continue Reading
Adobe's Strong Q3 Results Bolster Mixed Market Conditions

Updated Category News Views 141

U.S. Stock Market Overview This morning, the stock market in the U.S. registered mixed results, creating a patchwork of fortunes among various sectors. The Dow Jones index recorded a drop of over 50 points, showcasing the volatility present in the financial markets. Market Indices Performance Current Status After the market opened, the Dow noted a decline of 0.16%,...

Continue Reading
Wolters Kluwer's Recent Share Buyback Highlights

Updated Category News Views 233

Wolters Kluwer's Recent Share Buyback Program Wolters Kluwer, a global leader in professional information solutions, has been actively engaging in a share buyback program aimed at enhancing shareholder value. From July 17 to July 23, 2025, the company repurchased 190,651 ordinary shares at an impressive total cost of €26.6 million, resulting in an average share price of...

Continue Reading
Unlocking the Power of Biofertilizers for Carbon Sequestration

Updated Category News Views 133

Revolutionizing Agriculture Through Biofertilizers In today's world, where concerns about climate change grow more pressing, the agricultural sector is being called to action. Sustainable practices that not only maintain productivity but also contribute positively to the environment are increasingly crucial. Biofertilizers are emerging as key players in this initiative,...

Continue Reading